Hospital Universitario De Salamanca
- Address
- lock Available on a paid plan
Hematology Research at Hospital Universitario De Salamanca
Clinical research at Hospital Universitario De Salamanca focuses on Hemic and Lymphatic Diseases, with a strong emphasis on myelodysplastic syndrome in people with IPSS-R low- or intermediate-risk disease. The studies are designed to better understand treatment benefit and safety in a common blood disorder seen in the hematology setting.
- Evaluating a new oral azacitidine approach for myelodysplastic syndrome
- Comparing treatment effectiveness against best supportive care
- Assessing safety, response, and overall clinical value of a potential new therapy
This work aims to improve care for patients with lower-risk myelodysplastic syndrome by identifying more effective and practical treatment options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 25 therapeutic areas and 15 of 524 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 499 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 118 by active trials.
- 1Novartis Pharma AG14active
lock +117 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International36trials
lock +67 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario De Salamanca
lock Showing 1 of 479 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC trial | Fondazione GONO G.I. | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 524 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 50 | Unknown | 2015-06-15 | 2026-07-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.